Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case–control study
Open Access
- 2 August 2016
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 8 (1) , 102-112
Abstract
Background Although muscle mass declines with testosterone deficiency in men, previous studies of muscle function have not demonstrated consistent deficits, likely due to relatively insensitive methodology. Our objective was to determine the effects of testosterone deprivation on the biomechanical function of individual lower-limb muscles. Methods We conducted a 12-month prospective, observational case–control study of 34 men newly commencing androgen deprivation treatment (ADT) for prostate cancer and 29 age-matched prostate cancer controls. Participants were assessed at 0, 6, and 12 months while walking in a biomechanics laboratory. We combined video-based motion capture and ground reaction force data with computerized musculoskeletal modelling to assess the following primary outcomes: (i) peak joint torques at the hip, knee and ankle, and corresponding individual muscle forces; (ii) individual muscle contributions to acceleration of the body's centre of mass; and (iii) walking speed, stride length, and step width. A linear mixed model was used to compare mean differences between groups. Results Compared with controls over 12 months, men receiving ADT had a mean reduction in total testosterone level from 14.1 to 0.4 nmol/L, and demonstrated more marked decreases in peak hip flexor torque by 14% [mean difference −0.11 N/kg (−0.19, −0.03), P = 0.01] and peak knee extensor torque by 16% [−0.11 N/kg (−0.20, −0.02), P = 0.02] of the initial mean value. Correspondingly, iliopsoas force decreased by 14% (P = 0.006), and quadriceps force decreased by 11%, although this narrowly missed statistical significance (P = 0.07). Soleus decreased contribution to forward acceleration of the body's centre of mass by 17% [mean difference −0.17 m/s2 (−0.29, −0.05), P < 0.01]. No significant changes between groups were observed in other joint torques or individual muscle contributions to acceleration of the body. Step width increased by 18% [mean adjusted difference 1.4 cm (0.6, 27.4), P = 0.042] in the ADT group compared with controls, with no change in stride length or walking speed. Conclusions Testosterone deprivation selectively decreases lower-limb muscle function, predominantly affecting muscles that support body weight, accelerate the body forwards during walking, and mediate balance. Future exercise and pro-myogenic interventional studies to mitigate ADT-associated sarcopenia should target these deficits.Keywords
Funding Information
- National Health and Medical Research Council (1006407)
- Australian Research Council (DP1095366)
This publication has 33 references indexed in Scilit:
- Muscle and bone effects of androgen deprivation therapy: current and emerging therapiesEndocrine-Related Cancer, 2014
- Sarcopenia During Androgen-Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2012
- Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistanceAmerican Journal of Physiology-Endocrinology and Metabolism, 2011
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 StudyJournal of Clinical Oncology, 2011
- Low Free Testosterone Predicts Frailty in Older Men: The Health in Men StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Free Testosterone Levels Are Associated with Mobility Limitation and Physical Performance in Community-Dwelling Men: The Framingham Offspring StudyThe Journal of Clinical Endocrinology & Metabolism, 2010
- Sex Hormones and Frailty in Older Men: The Osteoporotic Fractures in Men (MrOS) StudyThe Journal of Clinical Endocrinology & Metabolism, 2009
- The reliability of three-dimensional kinematic gait measurements: A systematic reviewGait & Posture, 2009
- Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate CancerThe Journal of Clinical Endocrinology & Metabolism, 2005
- The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancerThe Aging Male, 2005